WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy

• Published in: Leukemia 2023-09, Vol.37 (9), p.1842-1849
• Main Authors: Fløisand, Yngvar, Remberger, Mats, Bigalke, Iris, Josefsen, Dag, Vålerhaugen, Helen, Inderberg, Else Marit, Olaussen, Richard W., Gjertsen, Bjørn Tore, Goedkoop, Rene, Geiger, Christiane, Prinz, Petra U., Schnorfeil, Frauke M., Pinkernell, Kai, Schendel, Dolores J., Kvalheim, Gunnar
• Format: Article
• Language: English
• Subjects: 13; 13/109; 631/67/1059; 692/308/575; Acute myeloid leukemia; Allografts; Antigens; Azacytidine; Cancer Research; Chemotherapy; Critical Care Medicine; Dendritic cells; Hematology; Hematopoietic stem cells; Intensive; Internal Medicine; Leukemia; Maintenance; Medicine; Medicine & Public Health; Oncology; Remission; Side effects; Stem cell transplantation; Stem cells; Survival; Transplantation; Vaccines
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/s41375-023-01980-3

Intensive induction chemotherapy achieves complete remissions (CR) in >60% of patients with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral azacytidine may be used as maintenance treatment in AML in first remission, but can be associated with substantial side effects, and less toxic strategies should be explored. Twenty AML patients in first CR (CR1) ineligible for allo-HSCT were treated with FDC101, an autologous RNA-loaded mature dendritic cell (mDC) vaccine expressing two leukemia-associated antigens (LAAs). Each dose consisted of 2.5–5 × 10 6 mDCs per antigen, given weekly until week 4, at week 6, and then monthly, during the 2-year study period. Patients were followed for safety and long-term survival. Treatment was well tolerated, with mild and transient injection site reactions. Eleven of 20 patients (55%) remained in CR, while 4 of 6 relapsing patients achieved CR2 after salvage therapy and underwent allo-HSCT. OS at five years was 75% (95% CI: 50–89), with 70% of patients ≥60 years of age being long-term survivors. Maintenance therapy with this DC vaccine was well tolerated in AML patients in CR1 and was accompanied by encouraging 5-year long-term survival.